Related Experiment Video

Updated: Jun 24, 2026

The Tail Suspension Test
10:17

The Tail Suspension Test

Published on: January 28, 2012

The association study of three FYN polymorphisms with prophylactic lithium response in bipolar patients

Aleksandra Szczepankiewicz1, Maria Skibinska, Aleksandra Suwalska

  • 1Department of Pediatric Pulmonology, Allergy and Clinical Immunology, IIIrd Department of Pediatrics, Poznan University of Medical Sciences, Poznan, Poland. alszczep@amp.edu.pl

Human Psychopharmacology
|March 31, 2009
PubMed

Insights

Genetic variations in the FYN gene show a marginal association with lithium response in bipolar disorder patients. While no significant links were found for two FYN polymorphisms, a trend suggested a worse response with a specific FYN genotype.

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • FYN is a protein kinase involved in NMDA receptor phosphorylation and BDNF/TrkB signaling.
  • Lithium's neuroprotective effects stem from inhibiting NMDA receptor-mediated glutamatergic transmission.
  • Understanding genetic factors influencing lithium response is crucial for bipolar disorder treatment.

Purpose of the Study:

  • To investigate the association between three FYN gene polymorphisms and prophylactic lithium response in bipolar patients.
  • To explore the role of FYN gene variations in predicting lithium treatment outcomes.

Main Methods:

  • Genotyping of three FYN polymorphisms using PCR-RFLP in 101 bipolar patients.
  • Categorization of patients into excellent, partial, and non-responders based on long-term lithium treatment.
  • Statistical analysis to compare genotype and allele frequencies between response groups.

Main Results:

  • No significant differences in genotype or allele frequencies were found for T/G and A/G FYN polymorphisms concerning lithium response.
  • A trend indicated an association between the TT genotype and T allele of the T/C polymorphism with poorer lithium response.
  • The study found only marginal associations between the analyzed FYN polymorphisms and lithium response.

Conclusions:

  • FYN gene polymorphisms demonstrate a limited association with prophylactic lithium response in bipolar disorder.
  • Further research is needed to elucidate the complex genetic underpinnings of lithium efficacy.
  • These findings contribute to understanding the genetic basis of bipolar disorder and lithium treatment response.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...